Femoral neuropathy

Summary

Femoral neuropathy (MONDO:0006759) is a disease and 2 clinical trials. A subtype of mononeuropathy — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 2

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	femoral neuropathy
Mondo ID	MONDO:0006759
MeSH	D020428
DOID	DOID:4196
NCIT	C27595
SNOMED CT	25690000
UMLS	C0751931
MedGen	148421
GARD	0024467
Anatomy (UBERON)	UBERON:0001267
Is cancer (heuristic)	no

Also known as: femoral nerve peripheral nerve lesion · peripheral nerve lesion of femoral nerve

Disease family

This is a subtype of mononeuropathy. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › peripheral nervous system disorder › peripheral neuropathy › mononeuropathy › femoral neuropathy

Related subtypes (6): radial neuropathy, mononeuritis simplex, peroneal neuropathy, sciatic neuropathy, tibial neuropathy, ulnar neuropathy

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 2.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01321138	Not specified	COMPLETED	Femoral Neuropathy After Anterior Cruciate Ligament Reconstruction: Femoral Nerve Block vs Patient-controlled Analgesia (PCA)
NCT04747119	Not specified	COMPLETED	Effect of MET on Meralgia Paraesthesia Postpartum Muscle Energy Technique